Publicações

Impact of Prior Therapy on Efficacy and Safety of Oral Ixazomib-Lenalidomide-Dexamethasone (Ird) Vs Placebo-Rd in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (Rrmm) in Tourmaline-Mm1.

AuthID
P-00R-HSM

Author(s)

Mateos, MV

Masszi, T

Grzasko, N

Hansson, M

Sandhu, I

Pour, L

Viterbo, L

Jackson, SR

Stoppa, AM

Gimsing, P

Hamadani, M

Borsaru, G

Berg, D

Lin, JC

Van De Velde, H

Richardson, PG

Moreau, P

Tipo de Documento

Abstract

Year published

2016

Publicado

in JOURNAL OF CLINICAL ONCOLOGY, ISSN: 0732-183X

Volume: 34, Número: 15

Conference

Annual Meeting of the American-Society-Of-Clinical-Oncology (Asco), Date: JUN 03-07, 2016, Location: Chicago, IL, Patrocinadores: Amer Soc Clin Oncol

Indexing

Wos^®

Google Scholar^®

Metadata
Fontes

Publication Identifiers

DOI: 10.1200/jco.2016.34.15_suppl.8039

Wos: WOS:000404711505194

Source Identifiers

ISSN: 0732-183X

Export Publication Metadata

Lista Marked

Adicionar à lista Marked

Info

At this moment we don't have any links to full text documens.

Impact of Prior Therapy on Efficacy and Safety of Oral Ixazomib-Lenalidomide-Dexamethasone (Ird) Vs Placebo-Rd in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (Rrmm) in Tourmaline-Mm1.

Links Úteis

Ajuda

Autenticação Federada (Clique na imagem)

Impact of Prior Therapy on Efficacy and Safety of Oral Ixazomib-Lenalidomide-Dexamethasone (Ird) Vs Placebo-Rd in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (Rrmm) in Tourmaline-Mm1.

Links Úteis

Ajuda